ENFUVIRTIDE

BRAND NAME	FUZEON
DRUG CLASS	Antiretroviral
AVAILABILITY	Vial contains 108 mg of enfuvirtide. Also contain sodium carbonate, mannitol, sodium hydroxide and hydrochloric acid.[1] Solvent vials contain 2 mL of water for injections.[1]
pH	9 when reconstituted[2]
PREPARATION	Reconstitute the vial with 1.1 mL of water for injections directed down the side of the vial. Tap the vial for 10 seconds and roll gently between the hands to mix well without foaming. **Do not shake.** Stand the vial until the powder is completely dissolved. This may take up to 45 minutes. Rolling the vial gently between the hands will reduce dissolution time.[1] The solution is clear and colourless. The final concentration is 90 mg/mL.[1]
STABILITY	Vial: store below 30 °C[1] Reconstituted solution: stable for 24 hours at 2 to 8 °C[1]
ADMINISTRATION	
IM injection	Not recommended
SUBCUT injection	Inject into upper arm, anterior thigh or abdomen. Rotate the site of injection. Suitable for self-administration after appropriate patient education.[1]
IV injection	Not recommended
IV infusion	Not recommended
COMPATIBILITY	No information
INCOMPATIBILITY	No information
SPECIAL NOTES	Injection-site reactions are very common, especially in the first week of therapy, and include pain and discomfort, erythema, nodules and cysts, pruritus and ecchymosis.[1] Hypersensitivity reactions have been reported. Symptoms may include rash, fever, nausea, vomiting, chills, rigors and hypotension. Anaphylaxis has been reported.[1]

REFERENCES

1. Product information.Available from www.tga.gov.au. Accessed 01/11/2019.
2. Fuzeon. US prescribing information. South San Francisco, CA: Genentech USA. Updated 08/2019. Available from www.dailymed.nlm.nih.gov. Accessed 01/11/2019